Rewiring cancer signaling to improve colorectal cancer therapy
Official title: REWIRE-CAN - Rewiring Cancer with Novel Signalling Therapies
Funded at Sloan-Kettering Inst Can Research · NIH-11505665 · Data updated 2026-11-12
A cancer research project in colorectal cancer aims to test new ways to reprogram cancer cell signaling to make treatments work better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | May 1, 2026 |
| Project end | April 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $2,122,620 |
| NIH project number | 1OT2CA320058-01 |
| Project ID | NIH-11505665 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with colorectal cancer, especially those whose disease involves the WNT, MAPK, and PI3K signaling pathways, may benefit from advances arising from this research.
✕Less likely to help
Patients whose cancer does not rely on the targeted pathways or who cannot tolerate experimental therapies may not benefit.
What this research studies
This program explores how turning up or tweak key cancer signaling pathways could make colorectal cancer cells more vulnerable to therapy. It combines ideas about hyperactivation of signaling with changing the state of cancer cells to improve responses to existing and new treatments. The team has experience translating basic findings into drug development and plans to test clinically relevant approaches. The work is designed to move toward therapies that patients could eventually receive in clinical settings.
Why it matters
Potential benefit: If successful, this approach could lead to new treatment strategies that make colorectal cancer more responsive to therapy.
How similar studies have gone: Previous work shows that manipulating oncogenic signaling can sensitize cancer cells to treatment, but this exact approach in CRC is investigational and promising.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Ganesh, Karuna — Sloan-Kettering Inst Can Research
- Study coordinator: Ganesh, Karuna
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.